The bispecific EGFR- and MET-directed subcutaneous coformulation produced a 42% objective response rate in the phase 1b/2 OrigAMI-4 trial for patients with pretreated recurrent or metastatic HNSCC.

This week, we break down 5 pivotal regulatory decisions. This includes FDA actions for daridorexant in pediatric insomnia and a gene therapy for Huntington disease, alongside an accelerated approval ...

HealthDay News — Utah has become the first state to let an artificial intelligence (AI) program prescribe medication without a doctor writing the prescription, starting with acne treatments.

The Association of Rheumatology Professionals (ARP) has developed programming highlighting the perspectives of ...

A celebrity's recent multiple sclerosis misdiagnosis highlights the complexities of medical liability and the error in judgment defense.

Ursodeoxycholic acid recommended as first-line therapy and to prevent recurrence after liver transplant for PBC.

Results from the phase 3 VOCAL study demonstrate that oral vadadustat dosed 3 times per week successfully maintains hemoglobin levels vs standard ESA therapy in adult hemodialysis patients.

Higher treatment satisfaction, better treatment retention, and fewer adverse events reported for those choosing their treatment.

HealthDay News — A simple vaginal swab may one day help women with abnormal bleeding learn whether they have endometrial cancer without first going through a painful biopsy.

The designation is based on phase 2 data demonstrating dose-dependent increases in total sleep time among children and adolescents, including those with comorbid neurodevelopmental disorders.

The sNDA is supported by findings from the phase 3 MANGROVE trial, which demonstrated a 43% reduction in the risk of disease progression or death compared with chemoimmunotherapy in stem cell ...

The Food and Drug Administration (FDA) has accepted and granted Priority Review to the Biologics License Application (BLA) for ifezuntirgene inilparvovec ...